INmune Bio Inc. share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro? for treatment of Alzheimer's Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS). Both patients, herein referred to as "Patient 1" and "Patient 2," was an original study participant in the Phase 1b clinical trial (ClinicalTrials.gov ID NCT03943264), in the target dose 1mg/kg cohort, which commenced in November of 2019 and completed in September of 2021.

In contrast to clinical trials, patients in the SAS receive exclusive care from their primary care physicians, with the Company's involvement limited to supplying XPro?. Reports from the primary care physicians indicate that XPro? has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.

Furthermore, the patients express a desire to continue receiving XPro? for Alzheimer's disease treatment. Patient 1 was diagnosed with AD at age 61 and enrolled in the Phase 1b clinical trials in December 2019 at age 63.

Patient 1 completed the 3-month Phase 1b open label trial and opted to enroll in the 12-month open label extension. His family members are keen to continue the management with XPro if available as they believe there is stability with the treatment." Patient 2 was diagnosed with AD at age 59 and enrolled in the Phase 1ss clinical trial in December 2019 at age 60. Patient 2 completed the 3-month Phase 2 clinical trial and opted to enroll in The 12-month open label extensions.

The primary care physician treating Patient 2 under the SAS has indicated [Patient 2's] cognitive decline has stopped, and he continues to do well. Additionally, the principal investigator who treated both patients previously commented on their response to XProTM as part of a webinar given by the Company describing the results of the AD01 Phase 1b trial in 2022 by clicking here (at 6:50 min mark). The Company remains on track in alignment with prior guidance for completing the current Phase 2 clinical trial investigating XProTM for treatment of AD in patients with biomarkers of inflammation.